Articles On Orthocell (ASX:OCC)

Orthocell (OCC) reports positive results from its crossover patient extension arm of its rotator cuff tendon clinical studyThe results demonstrated OrthoATI is a safe and effective treatment for patients suffering from rotator cuff tendinop...

ShareCafeResurgent ASX rallies: Aus shares 1.8% higher at noon By Lauren Hayes   At noon, the S&P/ASX 200 is 1.82 per cent or 117.70 points higher at 6579.70. The SPI futures are pointing to a rise of 116 points. Inflation data out toda...

Nasdaq-listed Biogen says its experimental Alzheimer’s drug study was successful The news sends ASX-listed Cogstate to soar Orthocell could have the first FDA-approved injectable cell therapy in orthopaedics  Big news out of Nasdaq-listed...

The ASX will open much higher on Thursday Wall Street rallied strongly overnight as yields slump following BoE’s decision The BoE has surprised the market with bond buyback announcement Local shares are set to open much higher on Thursday...

PYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical programs Orthocell gets first purchase orders The race is hotting up to develop the next RNA-based drug discovery, as a couple of ASX liste...

Orthocell (OCC) receives its first purchase orders for its Striate+ and Remplir products from partners BioHorizons and DVT, respectivelyStriate+ is used in guided bone and tissue regeneration procedures, and Remplir is a collagen nerve wrap...

Orthocell (OCC) appoints an exclusive Australian distributor for RemplirThe company penned a distributor agreement with Device Technologies, making the company its exclusive distributor for its peripheral nerve repair treatmentDevice Techno...

Perth-based regenerative medicine company Orthocell has inked a new deal with Device Technologies to distribute its nerve repair device in a bid to commercialise the technology across Australia and New Zealand.

ASX 200 drops load circa 1430 (AEST)  ends 0.4% lower Small caps index laughs openly in face of danger, gains 1% RBA hits us with another 50bps rate hike   The ASX 200 — not unlike the still, glassy ocean before a hurricane — was flat an...

DR BOREHAM’S CRUCIBLE: ORTHOCELL Market cap: $74.9m Shares on issue: 197,127,913 Chief executive officer: Paul Anderson Board: Dr Stewart Washer (chair), Mr Anderson, Matthew Callahan, Prof Lars Lidgren, Qi Xiao Zhou, Leslie Wise Finances (...

ShareCafeEvening Report: 21 July, 2022 by Paul Sanger   At the closing bell, the S&P/ASX 200 was 0.52 per cent or 35.10 points higher at 6794.30. The lithium and green metals sector was on fire today, after electric vehicle maker Tesla...

Orthocell (OCC) takes the next steps in its license and distribution agreements for its Striate+ dental membrane for bone regeneration   The exclusive patent and trademark licence agreement and distribution agreement is with Delaware corpo...

ShareCafeLunch Report: 21 July, 2022 by Paul Sanger   Australian shares are little changed in mixed trading this morning. At noon, the S&P/ASX 200 is 0.05 per cent or 3.60 points lower at 6755.60. Australian lithium and nickel companies...

ShareCafeStocks of the Hour: 21 July, 2022                  Orthocell (ASX:OCC) recently signed a global exclusive licence and distribution agreement with BioHorizons Implant Systems Inc, one of the largest dental implant companies in...

21 Jul 2022 - A snapshot of the stocks on the move featuring Orthocell (ASX:OCC), Telix Pharmaceuticals (ASX:TLX) and Asra Minerals (ASX:ASR).

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

ShareCafeOrthocell (ASX: OCC) – Webinar presentation Paul Anderson – Managing DIrector – Orthocell is a world-leading regenerative medicine company providing innovative products to restore mobility, function and performance. More Orthocell...

ShareCafeWebinar Recap – PCK, OCC, LCL & ICE Catch up on the full webinar presentations from PainChek (ASX: PCK), Orthocell (ASX: OCC), Los Cerros (ASX: LCL) & icetana (ASX: ICE) Webinar Recap – PCK, OCC, LCL & ICEStaff Writers

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

The ASX200 makes it four gains in a row The small cap index remains uninspired despite some strong individual performances HRL and 4DX deliver huge returns on Tuesday   The benchmark XJO is up by 0.6%. The little XEC index is not. The ASX...

Shares in regenerative medicine company Orthocell are flying after it signed a licencing and manufacturing deal worth $23.1 million with one of the world’s largest dental implant companies. 

Orthocell jumps 35% after signing global license deal Imricor in with Siemens deal on 3D imaging system CardieX submits “Pulse” application with US FDA  Orthocell (ASX:OCC) jumped by over 35% this morning after signing a 25-year exclusive...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Regenerative medicine company Orthocell (ASX:OCC) has entered into an exclusive patent and trademark license agreement and an exclusive distribution and supply agreement with BioHorizons Implant Systems.

It wasn’t exactly a red-letter day for the market as a whole, though – the ASX adding less than 0.5%, in spite of a beckoning smile from Wall Street overnight. Aussie markets opened to the news that The Nasdaq had posted a 1.62% gain, follo...

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

Orthocell’s (OCC) nerve reconstruction trial demonstrates the early recovery of muscle function in paralysed upper limbs The news follows the completion of Orthocell’s Remplir nerve reconstruction study on patients who suffered traumatic n...

Orthocell’s nerve reconstruction trial shows encouraging results Neuroscientific gets ethics approval to commence early-phase clinical trial Orthocell demonstrates encouraging trial results Orthocell (ASX:OCC) jumped 7% this morning after...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Managing director Paul Anderson said, “Remplir is the first of its kind biological scaffold designed by an Australian team of researchers to mimic the outer layer of the peripheral nerve and facilitate high-quality nerve repair."...

Regenerative medicine company Orthocell (OCC) receives regulatory approval for its Remplir peripheral nerve repair device to be introduced into the Australian nerve repair and regeneration market The approval includes Remplir on the Austra...

Orthocell’s Remplir device gets approval for the Australian Register of Therapeutic Goods (ARTG) Argenica’s study on lead drug ARG-007 is published in a medical journal The ASX 200 Health Index (XHJ) is trading lower by 0.50% at the time...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Regenerative medicine company Orthocell (ASX:OCC) has provided a US market entry update for the Striate+ premium dental membrane.

Orthocell (OCC) is set to scale up the manufacturing capacity of its Striate+ premium dental membrane Orthocell says it’s been actively preparing to increase its manufacturing capacity to greater than 100,000 units per year after receiving...

It has also received approvals to upgrade its existing facility and scale-up Striate+™ manufacturing capacity to more than 100,000 units per year. 

The company is focused on regenerating mobility for patients by developing innovative products for the repair of a variety of bone and soft tissue injuries.

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

“This is exciting research that opens up potential for novel treatments addressing significant unmet medical needs and we will explore these development options alongside our nerve repair applications."

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Ultimately, the new data supports the breadth of Orthocell’s cornerstone CelGro™ platform, with positive results recorded across nerve, tendon and bone repair studies.

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

The ASX had another day of solid gains, hitting a three week high with tech and resources leading the charge. The ASX 200 rose 1.25%, closing at 7,405 and while all sectors were in the green, resources and tech both were the best – gaining...

The Orthocell Ltd (ASX: OCC) share price is soaring today following news of clinical study success. At the time of writing, the Orthocell share price is trading hands at 58 cents, up 12.62%. Orthocell is developing new medical devices and...

The orthopaedic cell therapy company is in its strongest position yet to launch into the lucrative US market, worth an estimated US$4-5 billion.

Orthocell’s (OCC) latest study results reveal OrthoATI is more effective than steroid injection for treating rotator cuff tendon tears The announcement follows a randomised, multicentre, controlled rotator cuff tendon clinical study Patien...